Literature DB >> 27966087

Signaling pathways underlying the antidepressant-like effect of inosine in mice.

Filipe Marques Gonçalves1, Vivian Binder Neis1, Débora Kurrle Rieger2, Mark William Lopes1, Isabella A Heinrich3, Ana Paula Costa3, Ana Lúcia S Rodrigues1,3, Manuella P Kaster1, Rodrigo Bainy Leal4,5,6.   

Abstract

Inosine is a purine nucleoside formed by the breakdown of adenosine that elicits an antidepressant-like effect in mice through activation of adenosine A1 and A2A receptors. However, the signaling pathways underlying this effect are largely unknown. To address this issue, the present study investigated the influence of extracellular-regulated protein kinase (ERK)1/2, Ca2+/calmoduline-dependent protein kinase (CaMKII), protein kinase A (PKA), phosphoinositide 3-kinase (PI3K)/Akt, and glycogen synthase kinase 3beta (GSK-3β) modulation in the antiimmobility effect of inosine in the tail suspension test (TST) in mice. In addition, we attempted to verify if inosine treatment was capable of altering the immunocontent and phosphorylation of the transcription factor cyclic adenosine monophosphatate (cAMP) response-binding element protein (CREB) in mouse prefrontal cortex and hippocampus. Intracerebroventricular administration of U0126 (5 μg/mouse, MEK1/2 inhibitor), KN-62 (1 μg/mouse, CaMKII inhibitor), H-89 (1 μg/mouse, PKA inhibitor), and wortmannin (0.1 μg/mouse, PI3K inhibitor) prevented the antiimmobility effect of inosine (10 mg/kg, intraperitoneal (i.p.)) in the TST. Also, administration of a sub-effective dose of inosine (0.1 mg/kg, i.p.) in combination with a sub-effective dose of AR-A014418 (0.001 μg/mouse, GSK-3β inhibitor) induced a synergic antidepressant-like effect. None of the treatments altered locomotor activity of mice. Moreover, 24 h after a single administration of inosine (10 mg/kg, i.p.), CREB phosphorylation was increased in the hippocampus. Our findings provided new evidence that the antidepressant-like effect of inosine in the TST involves the activation of PKA, PI3K/Akt, ERK1/2, and CaMKII and the inhibition of GSK-3β. These results contribute to the comprehension of the mechanisms underlying the purinergic system modulation and indicate the intracellular signaling pathways involved in the antidepressant-like effect of inosine in a preclinical test of depression.

Entities:  

Keywords:  CREB; Depression; Inosine; Protein kinases; Signaling pathways

Mesh:

Substances:

Year:  2016        PMID: 27966087      PMCID: PMC5432480          DOI: 10.1007/s11302-016-9551-2

Source DB:  PubMed          Journal:  Purinergic Signal        ISSN: 1573-9538            Impact factor:   3.765


  85 in total

1.  Adenosine A2A receptors and depression.

Authors:  Malika El Yacoubi; Jean Costentin; Jean-Marie Vaugeois
Journal:  Neurology       Date:  2003-12-09       Impact factor: 9.910

2.  Vatairea macrocarpa lectin (VML) induces depressive-like behavior and expression of neuroinflammatory markers in mice.

Authors:  Filipe Marques Gonçalves; Andiara Espíndola Freitas; Tanara Vieira Peres; Débora Kurrle Rieger; Juliana Ben; Mariana Maestri; Ana Paula Costa; Ana Carolina Tramontina; Carlos Alberto Gonçalves; Ana Lúcia Severo Rodrigues; Celso Shiniti Nagano; Edson Holanda Teixeira; Kyria S Nascimento; Benildo Sousa Cavada; Rodrigo Bainy Leal
Journal:  Neurochem Res       Date:  2013-09-12       Impact factor: 3.996

3.  A role for MAP kinase signaling in behavioral models of depression and antidepressant treatment.

Authors:  Catharine H Duman; Lee Schlesinger; Masafumi Kodama; David S Russell; Ronald S Duman
Journal:  Biol Psychiatry       Date:  2006-08-30       Impact factor: 13.382

4.  Antidepressants activate CaMKII in neuron cell body by Thr286 phosphorylation.

Authors:  Ettore Tiraboschi; Roberto Giambelli; Giordano D'Urso; Antonio Galietta; Alessandro Barbon; Andrea de Bartolomeis; Massimo Gennarelli; Sergio Barlati; Giorgio Racagni; Maurizio Popoli
Journal:  Neuroreport       Date:  2004-10-25       Impact factor: 1.837

Review 5.  P2X receptors as drug targets.

Authors:  R Alan North; Michael F Jarvis
Journal:  Mol Pharmacol       Date:  2012-12-19       Impact factor: 4.436

6.  Antidepressant activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002) on learned helplessness in rats.

Authors:  Koji Yamada; Minoru Kobayashi; Shizuo Shiozaki; Teruko Ohta; Akihisa Mori; Peter Jenner; Tomoyuki Kanda
Journal:  Psychopharmacology (Berl)       Date:  2014-02-02       Impact factor: 4.530

7.  Region-specific alterations of AMPA receptor phosphorylation and signaling pathways in the pilocarpine model of epilepsy.

Authors:  Mark William Lopes; Samantha Cristiane Lopes; Ana Paula Costa; Filipe Marques Gonçalves; Débora Kurrle Rieger; Tanara Vieira Peres; Helena Eyng; Rui Daniel Prediger; Alexandre Paim Diaz; Jean Costa Nunes; Roger Walz; Rodrigo Bainy Leal
Journal:  Neurochem Int       Date:  2015-05-14       Impact factor: 3.921

8.  Inosine reduces ischemic brain injury in rats.

Authors:  Hui Shen; Guann-Juh Chen; Brandon K Harvey; Paula C Bickford; Yun Wang
Journal:  Stroke       Date:  2005-02-03       Impact factor: 7.914

9.  Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice.

Authors:  Angelo O Rosa; Manuella P Kaster; Ricardo W Binfaré; Susana Morales; Ester Martín-Aparicio; Maria Luisa Navarro-Rico; Ana Martinez; Miguel Medina; Antonio G García; Manuela G López; Ana Lúcia S Rodrigues
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2008-06-25       Impact factor: 5.067

10.  Involvement of PKA, PKC, CAMK-II and MEK1/2 in the acute antidepressant-like effect of creatine in mice.

Authors:  Mauricio P Cunha; Josiane Budni; Francis L Pazini; Ágatha Oliveira; Julia M Rosa; Mark W Lopes; Rodrigo B Leal; Ana Lúcia S Rodrigues
Journal:  Pharmacol Rep       Date:  2014-04-03       Impact factor: 3.024

View more
  4 in total

Review 1.  The ERK Pathway: Molecular Mechanisms and Treatment of Depression.

Authors:  John Q Wang; Limin Mao
Journal:  Mol Neurobiol       Date:  2019-02-09       Impact factor: 5.590

Review 2.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

3.  Glutamatergic system and mTOR-signaling pathway participate in the antidepressant-like effect of inosine in the tail suspension test.

Authors:  Filipe Marques Gonçalves; Vivian Binder Neis; Débora Kurrle Rieger; Tanara V Peres; Mark William Lopes; Isabella A Heinrich; Ana Paula Costa; Ana Lúcia S Rodrigues; Manuella P Kaster; Rodrigo Bainy Leal
Journal:  J Neural Transm (Vienna)       Date:  2017-07-10       Impact factor: 3.575

4.  Insight into the metabolic mechanism of Diterpene Ginkgolides on antidepressant effects for attenuating behavioural deficits compared with venlafaxine.

Authors:  Shunjie Bai; Xiaodong Zhang; Zhi Chen; Wei Wang; Qingchuan Hu; Zihong Liang; Peng Shen; Siwen Gui; Li Zeng; Zhao Liu; Jianjun Chen; Xiongfei Xie; Hua Huang; Yu Han; Haiyang Wang; Peng Xie
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.